Explanipedia

Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesions Open

Ksenia Kalyniuk, Tanja Fetter, Marie Grützbach, Tugce Guel, Natalija Novak , et al. · 2025

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease characterized by a type I interferon (IFN)-driven interface dermatitis in which cytotoxic lymphocytes invade the basal layer of the epidermis and induce the keratinocytic ce…

Beneath the surface: delineating the subtypes of Dowling–Degos disease Open

Sheetal Kumar, Damian J. Ralser, Joerg Wenzel, Jorge Frank, Regina C. Betz · 2025

Dowling–Degos disease (DDD) is a rare, genetically heterogeneous pigmentation disorder with an autosomal dominant pattern of inheritance. While DDD shows wide clinical variability, a defining feature is reticulate hyperpigmentation, which …

18F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer’s Disease Diagnosis Open

Yvonne Bouter, Robert M. Glasnek, Joerg Wenzel, Caroline Bouter · 2025

An early, biomarker-based diagnosis of Alzheimer’s Disease (AD) is crucial, especially with the emerging availability of novel therapeutic options. However, the role of 18 F-FDG-PET and its relationship to other PET and CSF biomarkers rema…

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study Open

T Witte, Ruth Fernandez‐Ruiz, Nadezda Abramova, Dominika Weinelt, Flavie Moreau , et al. · 2025

Objective To evaluate multiple-ascending doses of enpatoran, a selective toll-like receptor 7/8 (TLR7/8) inhibitor with the potential to modulate processes central to lupus pathophysiology, in patients with systemic and cutaneous lupus ery…

Rethinking deep learning in bioimaging through a data centric lens Open

Jiajun Cao, Joerg Wenzel, Shanghang Zhang, Josephine Lampe, Hongxiao Wang , et al. · 2025

Deep learning has become essential in bioimaging for tasks. By examining data-centric strategies in general AI and revisiting existing deep learning methods in bioimaging, we describe a prototypical “BioData-Centric AI” framework. For AI u…

LB0004 RANDOMISED, PLACEBO-CONTROLLED PHASE II STUDY OF ORAL ENPATORAN, A FIRST-IN-CLASS TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS Open

Eric F. Morand, Maria Dall’Era, Jorge Sánchez‐Guerrero, Dess Pearson, Victoria P. Werth , et al. · 2025

RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF ENPATORAN, A SMALL MOLECULE TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN CUTANEOUS LUPUS ERYTHEMATOSUS: RESULTS FROM COHORT A Open

David R. Pearson, Eric F. Morand, Joerg Wenzel, Richard Furie, Maria Dall’Era , et al. · 2025

O010 / #827 Topic: AS07 - Cutaneous Lupus Late-Breaking Abstract ABSTRACT CONCURRENT SESSION 01: FINDINGS FROM LUPUS CLINICAL TRIALS 22-05-2025 1:40 PM - 2:40 PM Background/Purpose No treatment is approved for cutaneous lupus erythematosus…

The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis Open

Susan Manzi, Jorge Sánchez‐Guerrero, Naoto Yokogawa, Joerg Wenzel, Josephine C Ocran-Appiah , et al. · 2025

Objective To investigate the effects of belimumab (BEL) on systemic lupus erythematosus (SLE) mucocutaneous and vasculitis manifestations. Methods This post hoc, integrated Belimumab Summary of Lupus Efficacy (Be-SLE) analysis pooled data …

Successful Treatment of Erythroderma in a Psoriasis Patient, Developed After Anti‐IL‐17, Anti‐IL‐23 and Anti‐IL‐4/IL‐13 Treatment, With Deucravacitinib Open

Tugce Guel, Luka de Vos‐Hillebrand, Dagmar Wilsmann‐Theis, Natalija Novak, Joerg Wenzel · 2025

We present the case of a 79‐year‐old female patient diagnosed with psoriasis who developed paradoxical drug reactions after administration of anti‐IL17 and anti‐IL‐23 inhibitors. Having shifted towards a rather eczematous phenotype, the pa…

Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib Open

Tanja Fetter, Dagmar Wilsmann‐Theis, Luka de Vos‐Hillebrand, Natalija Novak, Joerg Wenzel · 2024

We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily …

S2k‐Leitlinie: Diagnostik und Therapie der zirkumskripten Sklerodermie Open

Alexander Kreuter, Pia Moinzadeh, Maria Kinberger, Gerd Horneff, Margitta Worm , et al. · 2024

Zusammenfassung Die vorliegende aktualisierte S2k‐Leitlinie befasst sich mit der Diagnostik und der Therapie der zirkumskripten Sklerodermie (ZS). Diese umfasst ein Spektrum sklerotischer Erkrankungen der Haut mit, je nach Subtyp und Lokal…

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report Open

Tanja Fetter, Simon Fietz, Maya Bertlich, Christine Braegelmann, Luka de Vos‐Hillebrand , et al. · 2024

Introduction Over the past decade, immune checkpoint inhibitors such as antibodies against cytotoxicity T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have become an important armamentarium against a …

International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus Open

Minoru Hasegawa, François Chasset, Benjamin F. Chong, David Fiorentino, Manabu Fujimoto , et al. · 2024

The 5th International Conference of Cutaneous Lupus Erythematosus was held in Tokyo, Japan on May 9 and 10, 2023. The latest topics on the pathogenesis, diagnosis, assessment, and treatment of cutaneous lupus erythematosus, dermatomyositis…

S2k guideline: Diagnosis and therapy of localized scleroderma Open

Alexander Kreuter, Pia Moinzadeh, Maria Kinberger, Gerd Horneff, Margitta Worm , et al. · 2024

Summary The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation, structures such as adipose tis…

P102 Safety evaluation from an ongoing randomized, double-blind, multiple-ascending dose phase Ib study of enpatoran versus placebo in patients with active systemic or cutaneous lupus erythematosus (SLE/CLE) Open

Joerg Wenzel, Nadezda Abramova, Dominika Weinelt, Deborah Denis, Sanjeev Roy , et al. · 2024

Objective Enpatoran, a highly selective and potent toll-like receptor 7/8 inhibitor that has glucocorticoid-sparing potential, suppressed disease activity in mouse models of SLE and was well tolerated by healthy participants and patients w…

Update on pulse corticosteroid therapy for the management of alopecia areata Open

J. Bernhardt, Joerg Wenzel · 2024

Alopecia areata is a nonlife‐threatening autoimmune disorder and often requires systemic treatment to stop the disease from progressing. Pulse corticosteroid therapy (PCT) is a common way to treat severe alopecia areata although the exact …

Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study Open

Dagmar Wilsmann‐Theis, Rhena Funk, Rotraut Mößner, Thomas Bieber, Joerg Wenzel · 2023

Background: Methotrexate (MTX) in the therapy of psoriasis vulgaris (PV) is a well and long-established treatment option. Aims: To assess the long-term experience of individual patients in the real world with regard to the efficacy and saf…

Founder Variants in KRT5 and POGLUT1 Are Implicated in Dowling-Degos Disease Open

Sheetal Kumar, Oleg Borisov, Carlo Maj, Damian J. Ralser, Aytaj Humbatova , et al. · 2023

Dowling-Degos disease (DDD; MIM 179850, 615327, 615696, and 613736) is a rare, autosomal dominant skin pigmentation disorder ( Degos and Ossipowski, 1954 Degos R. Ossipowski B. Dermatose pigmentaire ŕeticulée des plis (discussion de l'acan…

LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus Open

Victoria P. Werth, Joseph F. Merola, Joerg Wenzel, Nikolay Delev, Harini Kothari , et al. · 2023

Background Deucravacitinib is a first-in-class, oral, selective, allosteric TYK2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis.¹−² Deucravacitinib demonstrated efficacy across multiple outcome m…

AB0574 LEVEL OF AGREEMENT ON CORE SIGNS OF CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) SUBTYPES AMONG DERMATOLOGISTS AND RHEUMATOLOGISTS AND DEVELOPMENT OF A CONCEPTUAL MODEL FOR CLE Open

Paul Kamudoni, Annegret Kuhn, Joseph F. Merola, Joerg Wenzel, Victoria P. Werth , et al. · 2023

Aberrant inflammasome activation as a driving force of human autoimmune skin disease Open

Tanja Fetter, Dennis Marinus de Graaf, Isabelle Claus, Joerg Wenzel · 2023

Autoimmune skin diseases are understood as conditions in which the adaptive immune system with autoantigen-specific T cells and autoantibody-producing B cells reacting against self-tissues plays a crucial pathogenic role. However, there is…

AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS Open

Victoria P. Werth, Joseph F. Merola, Joerg Wenzel, Nikolay Delev, Hema Kothari , et al. · 2023

Background Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis ^[1,2]. Deucravacitinib demonstrated …

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions Open

Dennis Niebel, Luka de Vos, Tanja Fetter, Christine Brägelmann, Joerg Wenzel · 2023

Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and …

Lupus erythematosus Open

Claudia Günther, Joerg Wenzel · 2023

Summary Cutaneous lupus erythematosus can manifest with or without systemic involvement resulting in a broad clinical spectrum. Disease pathogenesis is often characterized by a loss of tolerance to endogenous antigens and a chronic relapsi…

Lupus erythematodes Open

Claudia Günther, Joerg Wenzel · 2023

Zusammenfassung Der kutane Lupus erythematodes manifestiert sich mit oder ohne systemische Beteiligung mit einem breiten klinischen Spektrum. Die Pathogenese der Erkrankung ist durch einen Toleranzverlust gegenüber körpereigenen Antigenen …

Figure S2 from Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin Open